+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Cushing's Syndrome Diagnostic and Treatment Market - Forecasts from 2018 to 2023

  • ID: 4618292
  • Report
  • Region: Global
  • 80 Pages
  • Knowledge Sourcing Intelligence LLP
until Dec 31st 2019
1 of 3


  • Corcept Therapeutics Inc.
  • HRA Pharma
  • Novartis
  • StrongBridge Biopharma
  • MORE
The global Cushing’s Syndrome Diagnostic and Treatment market is expected to grow at a CAGR of 8.28% to reach a total market size of US$404.546 million by 2023, increasing from US$250.992 million in 2017. Cushing’s disease is a condition characterized by the presence of excess steroid hormone ‘cortisol’ or stress hormone in blood vessels and is caused by improper functioning of pituitary glands which are responsible for secreting adrenocorticotropic hormone (ACTH). ACTH stimulates the adrenal glands (located on top of the kidneys) to produce cortisol. Typical symptoms of the Cushing’s syndrome are weight gain, an appearance of pink or purple stretch marks and thinning and easily bruised skin and occasionally type 2 diabetes. Treatment includes reducing the use of corticosteroids, surgery, and medications.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top-down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the Cushing’s Syndrome diagnostic and treatment value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Cushing’s syndrome diagnostics and treatment market.

Major industry players profiled as part of the report are Novartis, Orphagen Pharmaceuticals, Inc., and Corcept Therapeutics among others.


In the report, Cushing’s syndrome diagnostic and treatment has been segmented by diagnostic techniques, by treatment, and by geography

By Diagnostic Techniques
  • 11 pm Salivary Cortisol Test
  • 24-hour Urine Free Cortisol
  • Overnight 1 mg Dexamethasone Suppression
By Treatment
  • Surgery
  • Radiation therapy
  • Medications
By Geography

North America
  • United States
  • Canada
South America
  • Brazil
  • Argentina
  • United Kingdom
  • Germany
  • France
Asia Pacific
  • China
  • India
  • Japan
Middle East and Africa
  • Saudi Arabia
  • Israel
Note: Product cover images may vary from those shown
2 of 3


  • Corcept Therapeutics Inc.
  • HRA Pharma
  • Novartis
  • StrongBridge Biopharma
  • MORE
1.1. Market Overview
1.2. Market Definition
1.3. Scope of Study
1.4. Currency
1.5. Assumptions

2. Research Methodology
2.1. Research Design
2.2. Research Sources

3. Executive Summary

4. Disease Overview
4.1. Introduction
4.2. Symptoms
4.3. Diagnosis
4.4. Treatment

5. Cushing’s Syndrome Diagnostic and Treatment Industry Overview
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.2. Epidemiology
5.3. Industry Value Chain Analysis
5.4. Industry regulations
5.5. Product Pipeline

6. Cushing’s Syndrome Diagnostic and Treatment Market Forecast by Diagnostic techniques
6.1. 11 p.m. Salivary Cortisol Test
6.2. 24 Hour Urine Free Cortisol Test
6.3. Overnight 1 mg Dexamethasone Suppression

7. Cushing’s Syndrome Diagnostic and Treatment Market Forecast by Treatment
7.1. Surgical Treatment
7.2. Radiation therapy
7.3. Medication

8. Cushing’s Syndrome Diagnostic and Treatment Market Forecast by Geography
8.1. North America
8.1.1. United States (US)
8.1.2. Canada
8.1.3. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.3. Europe
8.3.1. United Kingdom (UK)
8.3.2. Germany
8.3.3. France
8.3.4. Others
8.4. Asia Pacific
8.4.1. China
8.4.2. India
8.4.3. Japan
8.4.4. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. Israel

9. Competitive Intelligence
9.1. Market Share Analysis
9.2. Investment Analysis
9.3. Recent Deals
9.4. Strategies of Key Players

10. Company Profiles
10.1. Novartis
10.1.1. Overview
10.1.2. Products and Services
10.1.3. Financials
10.1.4. SWOT Analysis
10.2. Corcept Therapeutics Inc.
10.2.1. Overview
10.2.2. Products and Services
10.2.3. Financials
10.2.4. SWOT Analysis
10.3. StrongBridge Biopharma
10.3.1. Overview
10.3.2. Products and Services
10.3.3. Financials
10.3.4. SWOT Analysis
10.4. Orphagen Pharmaceuticals, Inc.
10.4.1. Overview
10.4.2. Products and Services
10.4.3. Financials
10.4.4. SWOT Analysis
10.5. HRA Pharma
10.5.1. Overview
10.5.2. Products and Services
10.5.3. Financials
10.5.4. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • Novartis
  • Corcept Therapeutics Inc.
  • StrongBridge Biopharma
  • Orphagen Pharmaceuticals, Inc.
  • HRA Pharma
Note: Product cover images may vary from those shown